#Ireland #Dublin #XIAFLEX #Dupuytren's Contracture #Keenova

Keenova's New Survey Presentation

Keenova Therapeutics plc, a key player in therapeutic development, has scheduled a presentation that promises to enhance knowledge surrounding Dupuytren's contracture (DC). This presentation will take place during the American Association for Hand Surgery (AAHS) Annual Meeting from January 13-17, 2026, where new survey findings will be unveiled to the medical community.

Understanding Dupuytren's Contracture

Dupuytren's contracture is a debilitating condition characterized by the thickening and shortening of tissue beneath the skin of the palm and fingers, leading to finger deformities. It affects a significant number of people, particularly those over 50 years old, and is estimated to impact around 13 million Americans.

Despite its prevalence, many patients are unaware of effective treatment options. Keenova’s survey aims to shed light on patients' experiences and perceptions regarding Dupuytren's contracture and its treatment, specifically focusing on the use of XIAFLEX® (collagenase clostridium histolyticum). This injectable therapy has been a pivotal development in managing the disease, yet awareness remains low.

Key Insights from the Survey

Conducted in March 2024, the survey gathered responses from 200 adults across the United States. The findings revealed several crucial insights:

• - Awareness and Education: A significant number of respondents did not realize that Dupuytren's contracture is treatable. This lack of awareness can result in delays in seeking necessary care, negatively impacting treatment outcomes.
• - Treatment Satisfaction: Among those who had undergone treatment, satisfaction levels were highest for patients receiving CCH injections, with many expressing regrets about not starting treatment sooner.
• - Importance of Dialogue: The results emphasize the need for improved communication between patients and healthcare providers. Enhanced conversations can empower patients to make informed decisions about their treatment options.

Dr. Philip Blazar, a renowned orthopedic surgeon and specialist, will lead the presentation, emphasizing the importance of educational initiatives in alleviating delays in diagnosis and treatment. The goal is to provide not only insights from this survey but also to foster discussions that can lead to better health outcomes.

Conclusion

As Keenova prepares for this pivotal presentation, the implications of these survey results could lead to significant advancements in the awareness and management of Dupuytren's contracture. By equipping both providers and patients with the necessary knowledge and resources, there is potential for improved recognition of the condition and enhanced patient outcomes.

The keen insights derived from this research highlight the role that patient education plays in healthcare. There is a strong need for healthcare systems to support better awareness and understanding of conditions such as Dupuytren's contracture, ensuring patients are encouraged to seek treatment when needed.

As the AAHS Annual Meeting approaches, the anticipation grows for more informative discourse surrounding Dupuytren's contracture, promising a future where affected individuals can achieve better health outcomes through timely intervention and comprehensive care.